CD166 has been reported to play a pro-carcinogenic role in liver cancer cells by promoting the expression and activation of RAC-alpha serine/threonine-protein kinase (AKT) and yes-associated protein (YAP), which is a coactivator of Hippo signaling [73,74]. The gene discussed is AKT1; the disease is liver cancer.